PRLD

Prelude Therapeutics INC

+$22.7M

Net Activity

Institutions Holding

55

Popularity Rank

#5756

Avg Weight

0.03%

Total Value

$105.3M

Ownership Trend

55 institutions currently hold PRLD, with 30 net buyers and 16 net sellers this quarter.

Institutional Moves

Institutional Moves (Q1 2026)

Majority Increased

Based on recent trading activity

Net Selling Institutions

16

Net Buying Institutions

30

Key Holders

View all 55 holding institutions

Quarterly Activity

Recent Activity

+$24.8M

Total Buy Value

$6.7M

Total Sell Value

New buy10
Trim11
Add20
Sold out5

30

Net Buyers

16

Net Sellers

Insider Trading (Form 4)

Form 144 Pre-Sale Notices

No Form 144 planned sale filings in the last 90 days

Beneficial Ownership (13D/13G)

No Schedule 13D/13G filings for this ticker

Material Events (8-K)

No Form 8-K filings for this ticker

FAQ

Who are the top institutional investors holding PRELUDE THERAPEUTICS INC (PRLD)?
Major stakeholders currently include Orbimed Advisors LLC ($37.3M), Baker Bros. Advisors LP ($34.6M), Kynam Capital Management, LP ($5.4M). Based on the latest 13F filings, there are a total of 55 tracked investment funds and institutions maintaining positions in PRLD.
What is the overall institutional sentiment toward PRLD recently?
Institutional sentiment appears Bullish (Net Buying). During the most recent reporting quarter, the stock experienced a net inflow of $22.7M, driven by 30 managers accumulating shares while 16 reduced their exposure.
Which institutions have been selling or reducing their PRLD positions?
In the latest period, 11 funds trimmed their holdings, and 5 managers completely exited their positions. The aggregate reported sell value was $6.7M.
Are there any notable investors adding PRLD to their portfolios?
Yes, buying activity remains notable. 10 institutions opened new positions in {ticker}, and 20 existing holders added to their shares. The total reported buy value for the quarter amounted to $24.8M.

Related Stocks